Long-term safety study after investigational heart cell treatment
Part of Genetic & congenital, Heart & circulation clinical trials.
This study looks at the long-term safety of an experimental treatment called JRM-001, which uses a patient's own heart cells to help repair the heart after surgery for congenital heart disease. It is for children who previously took part in an earlier study of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the previous study of JRM-001 for congenital heart disease.
- You either received the JRM-001 cells after a heart catheter procedure, or you had the catheter procedure alone (without the cells).
- You are able to visit the study site for follow-up visits.
- The study team can obtain your medical records from the hospital where you were treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an infusion of heart stem/progenitor cells can improve outcomes for children with a single working heart chamber (single ventricle) who are scheduled for the next surgical stage (Glenn or Fontan). It may help the heart function after surgery, but participation depends on several heart, lung, brain, and overall health safety criteria.
This trial studies whether a newer “tissue-engineered” blood vessel graft is safe and works well in children who need a specific heart surgery connection outside the heart. It may help by offering a new type of graft, but your team will screen for size and medical factors first.
This trial tests a gel that is injected directly into the heart muscle during the Stage II Glenn operation for children with Hypoplastic Left Heart Syndrome. The goal is to see if the gel is safe and can help the heart function better after surgery.
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
This Phase 1 study tests a treatment made from stem cells to grow heart muscle cells (“cardiomyocytes”) for people with long-lasting (chronic) heart weakness after a prior heart attack. It aims to see if the therapy can improve heart function and is safe in carefully selected patients.
This study tests a new treatment using donor stem cells injected into the heart during scheduled bypass surgery. The goal is to see if these cells help improve heart function in people with heart failure due to blocked arteries and a weak heart pump.
Hear when a new Single-ventricle trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.